Management of Gastrointestinal Stromal Tumors

Margaret von Mehren

doi:10.1016/j.suc.2016.05.011

Management of Gastrointestinal Stromal Tumors

Margaret von Mehren

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Gastrointestinal stromal tumors had the reputation for poor outcomes because of their lack of response to nonsurgical interventions. The discovery of gain-of-function mutations involving receptor tyrosine kinase growth factor receptors altered the biological understanding and management. Beginning in 2000, management of these tumors has changed dramatically because of the availability of tyrosine kinase inhibitors. The role of surgery continues to be refined. This article reviews how surgery and systemic therapy are being used, incorporating definitions of risk. Decisions on how to treat a patient is based on the risk of progression, pathologic characteristics, and tumor location.

Original language	English
Pages (from-to)	1059-1075
Number of pages	17
Journal	Surgical Clinics of North America
Volume	96
Issue number	5
DOIs	https://doi.org/10.1016/j.suc.2016.05.011
State	Published - Oct 1 2016

Keywords

Adjuvant therapy
GIST
KIT
Metastasectomy
Neoadjuvant therapy
PDGFRA
SDH-deficient GIST
Tyrosine kinase inhibitors

Access to Document

10.1016/j.suc.2016.05.011

Cite this

@article{c8cb8736cd2e4adb91e5ea5b2a14c1a5,

title = "Management of Gastrointestinal Stromal Tumors",

abstract = "Gastrointestinal stromal tumors had the reputation for poor outcomes because of their lack of response to nonsurgical interventions. The discovery of gain-of-function mutations involving receptor tyrosine kinase growth factor receptors altered the biological understanding and management. Beginning in 2000, management of these tumors has changed dramatically because of the availability of tyrosine kinase inhibitors. The role of surgery continues to be refined. This article reviews how surgery and systemic therapy are being used, incorporating definitions of risk. Decisions on how to treat a patient is based on the risk of progression, pathologic characteristics, and tumor location.",

keywords = "Adjuvant therapy, GIST, KIT, Metastasectomy, Neoadjuvant therapy, PDGFRA, SDH-deficient GIST, Tyrosine kinase inhibitors",

author = "{von Mehren}, Margaret",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = oct,

day = "1",

doi = "10.1016/j.suc.2016.05.011",

language = "English",

volume = "96",

pages = "1059--1075",

journal = "Surgical Clinics of North America",

issn = "0039-6109",

publisher = "W.B. Saunders",

number = "5",

}

TY - JOUR

T1 - Management of Gastrointestinal Stromal Tumors

AU - von Mehren, Margaret

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Gastrointestinal stromal tumors had the reputation for poor outcomes because of their lack of response to nonsurgical interventions. The discovery of gain-of-function mutations involving receptor tyrosine kinase growth factor receptors altered the biological understanding and management. Beginning in 2000, management of these tumors has changed dramatically because of the availability of tyrosine kinase inhibitors. The role of surgery continues to be refined. This article reviews how surgery and systemic therapy are being used, incorporating definitions of risk. Decisions on how to treat a patient is based on the risk of progression, pathologic characteristics, and tumor location.

AB - Gastrointestinal stromal tumors had the reputation for poor outcomes because of their lack of response to nonsurgical interventions. The discovery of gain-of-function mutations involving receptor tyrosine kinase growth factor receptors altered the biological understanding and management. Beginning in 2000, management of these tumors has changed dramatically because of the availability of tyrosine kinase inhibitors. The role of surgery continues to be refined. This article reviews how surgery and systemic therapy are being used, incorporating definitions of risk. Decisions on how to treat a patient is based on the risk of progression, pathologic characteristics, and tumor location.

KW - Adjuvant therapy

KW - GIST

KW - KIT

KW - Metastasectomy

KW - Neoadjuvant therapy

KW - PDGFRA

KW - SDH-deficient GIST

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84990890517&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000383637100012&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.suc.2016.05.011

DO - 10.1016/j.suc.2016.05.011

M3 - Review article

C2 - 27542643

SN - 0039-6109

VL - 96

SP - 1059

EP - 1075

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

IS - 5

ER -

Management of Gastrointestinal Stromal Tumors

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this